Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Chemotherapy + Low-dose Radiotherapy for ES-SCLC
NCT07583550Phase 2Recruiting
- Sponsor
- Jiangmen Central Hospital
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Jiangmen Central Hospital. Started Jul 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07583550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583550.